High Concentrations of Nelfinavir as an Independent Risk Factor for Lipodystrophy in Human Immunodeficiency Virus-Infected Patients
Open Access
- 1 December 2002
- journal article
- clinical trial
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 46 (12) , 4009-4012
- https://doi.org/10.1128/aac.46.12.4009-4012.2002
Abstract
To assess the relationship between antiretroviral drug exposure and lipodystrophy, 69 human immunodeficiency virus type 1-infected patients receiving nelfinavir were investigated cross-sectionally. Lipodystrophy was defined by patients' self-report. Nelfinavir trough concentrations in plasma were significantly related to overall lipodystrophy and peripheral fat wasting scores and appeared to be an independent risk factor for lipodystrophyKeywords
This publication has 6 references indexed in Scilit:
- Estimation of body fat from skinfold thicknessComputer Methods and Programs in Biomedicine, 2001
- Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterationsAIDS, 1999
- Inhibition of Adipocyte Differentiation by HIV Protease InhibitorsJournal of Clinical Endocrinology & Metabolism, 1999
- Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort studyThe Lancet, 1999
- Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 YearsBritish Journal of Nutrition, 1974
- The metabolic effects, and the composition of the tissue lost, in weight reduction by obese patients on treatment with fenfluramineBritish Journal of Pharmacology, 1973